Compare SpaceX (SPCX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SpaceX vs Zoetis Inc — how do they compare? SpaceX trades at $124.86 (market cap $1.58T), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: SpaceX is far larger — about 49.5× Zoetis Inc's market cap, and Zoetis Inc pays a 2.78% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| SPCX | ZTS | |
|---|---|---|
Market Cap | $1.58T | $31.95B |
Sector | Technology | Health |
52-Week High | $202.09 | $156.76 |
52-Week Low | $119.85 | $71.91 |
Enterprise Value | $1.59T | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCX trades at $119.85, down 3.34% over 24 hours amid volatile post-IPO performance. The stock shows mixed technical signals with bearish moving averages but bullish oscillators. Fundamentally, the company reported a net loss of $4.94B on $18.67B revenue in 2025, with negative margins and elevated valuation ratios. Recent news highlights upcoming earnings on August 4, 2026, and a significant share unlock event, contributing to heightened investor attention and short interest.
Despite current losses, analyst consensus remains strongly bullish with a $237.78 price target, citing long-term AI infrastructure potential. Key risks include high short interest, lock-up expirations, and execution challenges in scaling profitability. The stock presents a high-risk, high-reward opportunity dependent on future earnings improvements and market sentiment shifts.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
